CN108047206A - Pivaloyl amino benzo [d] azepine * bases quinazoline compounds and preparation and application - Google Patents
Pivaloyl amino benzo [d] azepine * bases quinazoline compounds and preparation and application Download PDFInfo
- Publication number
- CN108047206A CN108047206A CN201810070298.1A CN201810070298A CN108047206A CN 108047206 A CN108047206 A CN 108047206A CN 201810070298 A CN201810070298 A CN 201810070298A CN 108047206 A CN108047206 A CN 108047206A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- solvent
- organic solvent
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*c(c(OC)cc(C(C1)c(cc2)ccc2OC)c2CCN1c(c1c3)ncnc1ccc3NC(c(cc1)ccc1I)=*)c2Cl Chemical compound C*c(c(OC)cc(C(C1)c(cc2)ccc2OC)c2CCN1c(c1c3)ncnc1ccc3NC(c(cc1)ccc1I)=*)c2Cl 0.000 description 1
- URQJRLMDYDQBEM-CXUHLZMHSA-N COc1ccc(C(CN(CC2)c(c3c4)ncnc3ccc4NC(/C=C/c3ccccc3)=O)c(cc3OC)c2c(Cl)c3OC)cc1 Chemical compound COc1ccc(C(CN(CC2)c(c3c4)ncnc3ccc4NC(/C=C/c3ccccc3)=O)c(cc3OC)c2c(Cl)c3OC)cc1 URQJRLMDYDQBEM-CXUHLZMHSA-N 0.000 description 1
- UFMIVVFSIVCIED-UHFFFAOYSA-N COc1ccc(C(CN(CC2)c3c(cc(cc4)NC(c5cc(OC)ccc5)=O)c4ncn3)c(cc3OC)c2c(Cl)c3OC)cc1 Chemical compound COc1ccc(C(CN(CC2)c3c(cc(cc4)NC(c5cc(OC)ccc5)=O)c4ncn3)c(cc3OC)c2c(Cl)c3OC)cc1 UFMIVVFSIVCIED-UHFFFAOYSA-N 0.000 description 1
- BDTBKXIFLIRSOH-UHFFFAOYSA-N COc1ccc(C(CN(CC2)c3ncnc4ccccc34)c(cc3OC)c2c(Cl)c3OC)cc1 Chemical compound COc1ccc(C(CN(CC2)c3ncnc4ccccc34)c(cc3OC)c2c(Cl)c3OC)cc1 BDTBKXIFLIRSOH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of pivaloyl amino benzo [d] azepinesBase quinazoline compounds and preparation and application.Pivaloyl amino benzo [d] azepine provided by the inventionBase quinazoline compounds are respectively provided with significant inhibitory activity to Breast cancer lines MCF 7, human lung carcinoma cell line A 549, people in loop strain HL 60 or human cervical carcinoma cell lines Siha, are expected to be applied to prepare in prevention or treatment human breast carcinoma, human lung cancer, human leukemia or the drug of human cervical carcinoma.The present invention provides pivaloyl amino benzo [d] azepines
Description
(1) technical field
The present invention relates to a kind of quinazoline compounds and its application, more particularly to a kind of pivaloyl amino benzo [d] nitrogen
It is miscellaneousBase quinazoline compounds and preparation method thereof and the compound are preparing the drug of prevention or treatment tumor disease
In application.
(2) background technology
Quinazoline compounds have many preferable bioactivity, have a wide range of applications in field of medicaments, and especially one
The quinazoline derivative of a little special constructions has apparent antiviral activity, antibacterial activity, antitumor activity etc., quinazoline ditosylate salt
Compound has had listed some kinds as antitumor drug.Such as the Gefitinib for being used to treat lung cancer of listing
(Gefitinib) and Tarceva (Erlotinib) and for treating the Lapatinib of breast cancer (Lapatinib), they
Belong to quinazoline compounds.Also common document report (refers to Y.- for new quinazoline compounds and its bioactivity
Y.Ke,H.-Y.Shiao,Y.C.Hsu,C.-Y.Chu,W.-C.Wang,Y.-C.Lee,W.-H.Lin,C.-H.Chen,
J.T.A.Hsu,C.-W.Chang,C.-W.Lin,T.-K.Yeh,Y.-S.Chao,M.S.Coumar,H.-P.Hsieh,
ChemMedChem 2013,8,136-148;A.Garofalo,A.Farce,S.Ravez,A.Lemoine,P.Six,
P.Chavatte,L.Goossens,P.Depreux,J.Med.Chem.2012,55,1189-1204).Certainly majority quinazoline
Class compound does not simultaneously have antitumor activity.
(3) content of the invention
It is an object of the invention to provide a kind of novel quinazoline quinoline class compound-pivaloyl amino with active anticancer
Benzo [d] azepineBase quinazoline compounds and its preparation method and application, such compound is under doses to people's lung
Cancer cell line A-549, MCF-7 cell strainHJ2mm, people in loop strain HL-60 or human cervical carcinoma cell lines
Siha Zhuo has significant inhibiting rate;And such compounds process for production thereof is easy, easily operated, raw material is easy to get, and production cost
It is relatively low, suitable for industrial applications.
For achieving the above object, the present invention adopts the following technical scheme that:
In a first aspect, the present invention provides pivaloyl amino benzo [d] azepines shown in a kind of formula (I)Base quinazoline ditosylate salt
Compound,
Second aspect, the present invention provide pivaloyl amino benzo [d] azepine shown in a kind of formula (I)Base quinazoline ditosylate salt
The preparation method of object is closed, the method is:(1) compound shown in formula (II) with compound shown in formula (III) is mixed, had
In solvent A, under the action of basic catalyst B, 25~120 DEG C reacted (TLC tracking and monitorings, solvent be acetic acid second
Ester/petroleum ether=1:3 (v/v), preferably 40~100 DEG C 0.5~12h of reaction), after the reaction was complete, reaction solution is isolated and purified, is made
Obtain compound shown in formula (IV);The organic solvent A is selected from one of following:Chloroform, toluene, methanol, ethyl alcohol, propyl alcohol, isopropanol,
Acetonitrile or N,N-dimethylformamide;The basic catalyst B is selected from one of following:Pyridine, diethylamine, triethylamine, quinoline,
N, N- dimethylaniline, 4-dimethylaminopyridine, 4- pyrollidinopyridines or sodium carbonate (preferably pyridine, diethylamine, triethylamine, N,
N- dimethylanilines or 4-dimethylaminopyridine);
(2) formula (IV) compound represented under reducing agent E effects, has been reacted in organic solvent D at 25~100 DEG C
(TLC tracking and monitorings, solvent are ethyl acetate/petroleum ether=1 entirely:1 (v/v), preferably 40~80 DEG C 0.5~12h of reaction), instead
Liquid is answered to filter, formula (V) compound represented is made in the concentrate drying (preferably 25 DEG C vacuum drying) after filtrate decompression concentration;
The organic solvent D is one of following:Chloroform, toluene, methanol, ethyl alcohol, propyl alcohol, isopropanol, acetonitrile or N, N- dimethyl formyl
Amine;The reducing agent E is one of following:Iron powder/concentrated hydrochloric acid, iron powder/acetic acid, palladium carbon/ammonium formate or palladium carbon/hydrazine hydrate;It is described
Iron powder/concentrated hydrochloric acid refers to that the mixing of iron powder and concentrated hydrochloric acid arbitrary proportion, iron powder/acetic acid refer to the mixed of iron powder and acetic acid arbitrary proportion
It closes, the palladium carbon/ammonium formate refers to the mixing of palladium carbon and ammonium formate arbitrary proportion, and the palladium carbon/hydrazine hydrate is palladium carbon and hydration
The mixture of hydrazine arbitrary proportion;
(3) compound shown in formula (V) is mixed with pivaloyl chloride or pivalic acid acid anhydride, under basic catalyst F effects, in
In organic solvent G, -10~50 DEG C the reaction was complete, and (TLC tracking and monitorings, solvent are ethyl acetate/petroleum ether=1:1 (v/v),
It is preferred that -10~50 DEG C of 3~12h of reaction), reaction solution is post-treated, and formula (I) compound represented is made;The base catalysis
Agent F is one of following:Pyridine, diethylamine, triethylamine, quinoline, N, N- dimethylanilines, 4-dimethylaminopyridine, 4- pyrrolidinyls
Pyridine or sodium carbonate;The organic solvent G is one of following:Tetrahydrofuran, dichloromethane, chloroform, ethyl acetate, ether, second
Nitrile, toluene or benzene.
Further, in step (1), compound shown in compound shown in the formula (III) and formula (II), basic catalyst B
The ratio between the amount of substance of feeding intake is 1.0 ﹕, 0.8~1.2 ﹕ 1.0~8.0.
Further, in step (1), the dosage of the organic solvent A is calculated as 10 with the quality of compound shown in formula (III)~
50mL/g。
Further, the method that reaction solution isolates and purifies described in step (1) of the present invention is:After the reaction was complete, by reaction solution
Solvent is evaporated off, concentrate is taken to be dissolved with organic solvent C, obtain lysate, then into lysate add in concentrate 1.0~
After mixing, solvent is evaporated off in the column chromatography silica gel of 2.0 times of weight, dry, the mixture of concentrate and silica gel is obtained, by mixture
Column is filled, then using volume ratio as 1:0.1~10 petroleum ether is eluant, eluent with ethyl acetate mixture, is collected containing target components
Efflux (preferably with ethyl acetate/petroleum ether=1:3 (v/v) are solvent tracing detection, collect target components, preferably receive
Collect the component that Rf values are 0.5), it is concentrated under reduced pressure, dry (preferably 50 DEG C of dryings) obtain formula (IV) compound represented;It is described to have
Solvent C is one of following:Ethyl alcohol, chloroform, tetrahydrofuran or ethyl acetate.The organic solvent C dosages are so as to dissolving is residual
Stay object.
Further, in step (2), when the reducing agent E is iron powder/concentrated hydrochloric acid or iron powder/acetic acid, formula (IV) institute
The mass ratio that feeds intake of iron powder, concentrated hydrochloric acid or acetic acid in the compound and reducing agent E shown is 1.0 ﹕, 1.0~3.0 ﹕ 0.2~1.0.
In the present invention, concentrated hydrochloric acid mass concentration is 36%~38%, and acetic acid uses glacial acetic acid.
Further, in step (2), when the reducing agent E is palladium carbon/ammonium formate or palladium carbon/hydrazine hydrate, formula (IV) institute
The compound shown in reducing agent E palladium carbon, ammonium formate or hydrazine hydrate feed intake mass ratio for 1.0 ﹕, 0.1~0.5 ﹕ 1.0~
3.0.The mass loading amount of palladium is 2~10%, preferably 5% in the palladium carbon being applicable in the present invention, hydrazine hydrate mass concentration for 40~
80%, preferably 80%.
Further, in step (2), the dosage of the organic solvent D is calculated as 10 with the quality of formula (IV) compound represented
~50mL/g.
Further, in step (3), compound shown in the formula (V) and pivaloyl chloride or pivalic acid acid anhydride, base catalysis
The ratio between amount for the substance that feeds intake of agent F is 1 ﹕, 1.0~8.0 ﹕ 1.0~3.0.
Further, in step (3), the dosage of the organic solvent G is calculated as 11 with the quality of compound shown in formula (V)~
100mL/g。
Further, the specific recommendation step (3) of the present invention carries out as follows:Under the conditions of -10~10 DEG C, toward formula
(V) in the organic solvent G solution of compound shown in and basic catalyst F or toward compound and base catalysis shown in formula (V)
The organic solvent G solution of pivaloyl chloride or pivalic acid acid anhydride is added dropwise in agent F, drop finishes, and when -10~50 DEG C of reactions 3~12 are small, gained is anti-
Answer liquid is post-treated to obtain compound shown in formula (I);The organic solvent volume dosage of pivaloyl chloride or pivalic acid acid anhydride is dissolved to this
Invention does not influence, and total dosage of the organic solvent G is calculated as 11~100mL/g with the quality of compound shown in formula (V).It is organic
Total dosage of solvent G refer to dissolve the organic solvent G of compound shown in basic catalyst F and formula (V) and dissolving pivaloyl chloride or
The total volume of pivalic acid acid anhydride organic solvent G.
Further, the method for step (3) the of the present invention reaction solution post processing is:After the reaction was complete, by reacting liquid filtering,
Filtrate steaming removal solvent takes concentrate to be dissolved with organic solvent H, obtains lysate, concentrate is then added in into lysate
After mixing, solvent is evaporated off in the column chromatography silica gel of 1.0~2.0 times of weight, dry, obtains the mixture of concentrate and silica gel, will be mixed
Object dress column is closed, then using volume ratio as 1:0.1~10 petroleum ether is eluant, eluent with ethyl acetate mixture, is collected containing target
The efflux of component is (preferably with ethyl acetate/petroleum ether=1:1 (v/v) is solvent tracing detection, collects target components), subtract
Pressure concentration, dry (preferably 50 DEG C of dryings) obtain formula (I) compound represented;The organic solvent H is one of following:Ethyl alcohol,
Chloroform, tetrahydrofuran or ethyl acetate.The organic solvent H dosages are so as to dissolution residual substance.
Organic solvent A of the present invention, C, D, G and H are organic solvent, organic used in different step for the ease of distinguishing
Solvent is different and names, and letter itself does not have meaning;The catalyst B, reducing agent E and catalyst F are catalyst, in order to just
It is named in differentiation different step used catalyst difference, letter itself does not have meaning.
The third aspect, the invention further relates to pivaloyl amino benzo [d] azepines shown in formula (I)Base quinazoline compounds
Application in prevention or tumor is prepared, particularly useful for making answering in prevention or treatment human breast carcinoma drug
With.
Preferably, the drug is with the drug for inhibiting MCF-7 cell strainHJ2mm activity.Provided by the inventionization
Close object (I) has preferable inhibition to MCF-7 cell strainHJ2mm.
Pivaloyl amino benzo [d] azepine shown in formula (I) of the present inventionBase quinazoline compounds are also to human lung cancer
Cell line A-549, people in loop strain HL-60 or human cervical carcinoma cell lines Siha have significant inhibitory action,
It can be applied to prepare prevention or treat in human lung cancer, human leukemia or the drug of human cervical carcinoma.
The beneficial effects are mainly as follows:(1) pivaloyl amino benzo [d] azepine of the present inventionBase quinoline
The active anticancer that oxazoline compound (I) has had is expected to be applied in the drug for preparing prevention or treatment tumor disease, especially
It is the application in human breast carcinoma, human lung cancer, human leukemia or human cervical carcinoma's drug;(2) pivaloyl aminobenzene provided by the invention
And [d] azepineThe preparation method of base quinazoline compounds (I), simple easily operated, raw material is easy to get, and production cost compared with
It is low, suitable for practicality.
(4) specific embodiment
The present invention be further described in conjunction with specific embodiments, following embodiment illustrate the present invention rather than
It limit the invention in any way.
Compound (II) prepare reference literature (Weinstock, J.et al.J.Med.Chem., 1986,29 (11),
Method 2315-2325) is prepared.The chloro- 6- nitro-quinazolines (III) of 4- prepare reference literature (Fernandes, C.et
Al.Bioorg.Med.Chem., 2007,15 (12), 3974-3980) method be prepared.
Palladium carbon (Pd/C) model D5H5A that the embodiment of the present invention uses, is purchased from Shaanxi Ruike New Materials Co., Ltd..
Embodiment 1:Nitro benzo [d] azepineThe preparation of base quinazoline (IV)
Successively by the chloro- 6- nitro-quinazolines (III) of 1.20 grams of (5.73mmol) 4- and 2.39 grams of (6.87mmol) compounds
(II), 3.62 grams of (45.76mmol) pyridines, 12 milliliters of chloroforms are added in 50 milliliters of reaction bulb, are heated to 40 DEG C, TLC tracking
(solvent is ethyl acetate/petroleum ether=1 for detection:3 (v/v)), be stirred to react 10 it is small when, close reaction, reaction solution is evaporated off molten
Agent adds in 10 milliliters of ethyl acetate in obtained concentrate and is dissolved, obtains lysate, 3.0 grams of columns are added in into lysate
Chromatographic silica gel (300~400 mesh column chromatography silica gel) after mixing, is evaporated off solvent, obtains the mixture of dry concentrate and silica gel,
Mixture is filled into column, then using volume ratio as 1:10 petrol ether/ethyl acetate mixed solution is eluant, eluent, is eluted, TLC tracking
(solvent is ethyl acetate/petroleum ether=1 for detection:3 (v/v)), it is collected according to TLC detections containing formula (IV) compound represented
Eluent (Rf values are 0.5), collection liquid concentration, 50 DEG C are dried to obtain the faint yellow solid product shown in formula (IV), yield
85.1%, 164~166 DEG C of fusing point.1H NMR(500MHz,CDCl3)δ:3.32-3.38 (m, 1H), 3.63 (dt, J=3.4,
15.5Hz, 1H), 3.75 (s, 3H), 3.82 (s, 6H), 3.91 (dd, J=8.1,14.3Hz, 1H), 4.03 (td, J=4.1,
11.7Hz, 1H), 4.15 (d, J=11.5Hz, 1H), 4.72 (dd, J=8.3,14.2Hz, 1H), 5.14 (t, J=8.9Hz,
1H), 6.60 (s, 1H), 6.90 (d, J=8.7Hz, 2H), 7.08 (d, J=8.6Hz, 2H), 7.93 (d, J=9.1Hz, 1H),
8.48 (dd, J=2.4,9.2Hz, 1H), 8.71 (s, 1H), 8.96 (d, J=2.4Hz, 1H).IR(KBr,cm-1)ν:2917,
2848,1616,1580,1510,1463,1355,1327,1249,1038,847。
Embodiment 2:Nitro benzo [d] azepineThe preparation of base quinazoline (IV)
Successively by the chloro- 6- nitro-quinazolines (III) of 1.20 grams of (5.73mmol) 4- and 1.59 grams of (4.57mmol) compounds
(II), 1.67 grams of (22.83mmol) diethylamine, 60 milliliters of toluene are added in 100 milliliters of three-necked flask, are heated to 100 DEG C,
(solvent is ethyl acetate/petroleum ether=1 to TLC tracing detections:3 (v/v)), be stirred to react 2 it is small when, close reaction, reaction solution
Solvent is evaporated off, 20 milliliters of ethyl alcohol are added in obtained concentrate and are dissolved, obtain lysate, 2.5 grams are added in into lysate
Column chromatography silica gel (300~400 mesh column chromatography silica gel) after mixing, is evaporated off solvent, obtains the mixing of dry concentrate and silica gel
Mixture is filled column, then using volume ratio as 1 by object:5 petrol ether/ethyl acetate mixed solution be eluant, eluent, elution, TLC with
(solvent is ethyl acetate/petroleum ether=1 for track detection:3 (v/v)), it is collected according to TLC detections containing formula (IV) compound represented
Eluent (Rf values be 0.5), collection liquid concentration, 50 DEG C are dried to obtain the faint yellow solid product shown in formula (IV), yield
72.6%, 164~166 DEG C of fusing point.1H NMR and IR is the same as embodiment 1.
Embodiment 3:Nitro benzo [d] azepineThe preparation of base quinazoline (IV)
Successively by the chloro- 6- nitro-quinazolines (III) of 1.20 grams of (5.73mmol) 4- and 1.99 grams of (5.72mmol) compounds
(II), 0.58 gram of (5.73mmol) triethylamine, 60 milliliters of ethyl alcohol are added in 100 milliliters of three-necked flask, are heated to 60 DEG C, TLC
(solvent is ethyl acetate/petroleum ether=1 to tracing detection:3 (v/v)), be stirred to react 8 it is small when, close reaction, reaction solution is evaporated off
Solvent adds in 20 milliliters of chloroforms in obtained concentrate and is dissolved, obtains lysate, 2.5 grams of column layers are added in into lysate
Silica gel (300~400 mesh column chromatography silica gel) is analysed, after mixing, solvent is evaporated off, obtains the mixture of dry concentrate and silica gel, it will
Mixture fills column, then using volume ratio as 10:1 petrol ether/ethyl acetate mixed solution is eluant, eluent, and elution, TLC, which is tracked, to be examined
(solvent is ethyl acetate/petroleum ether=1 for survey:3 (v/v)), it is detected according to TLC and collects washing for (IV) compound represented Han formula
De- liquid (Rf values are 0.5), collection liquid concentrates, and 50 DEG C are dried to obtain the faint yellow solid product shown in formula (IV), yield 77.2%,
164~166 DEG C of fusing point.1H NMR and IR is the same as embodiment 1.
Embodiment 4:Nitro benzo [d] azepineThe preparation of base quinazoline (IV)
Successively by the chloro- 6- nitro-quinazolines (III) of 1.20 grams of (5.73mmol) 4- and 2.20 grams of (6.32mmol) compounds
(II), 1.40 grams of (11.46mmol) 4-dimethylaminopyridine, 60 milliliters of isopropanols are added in 100 milliliters of three-necked flask, room temperature
25 DEG C of stirrings, (solvent is ethyl acetate/petroleum ether=1 to TLC tracing detections:3 (v/v)), when reaction 12 is small, reaction is closed,
Solvent is evaporated off in reaction solution, and 20 milliliters of tetrahydrofurans are added in obtained concentrate and are dissolved, lysate are obtained, into lysate
4.0 grams of column chromatography silica gels (300~400 mesh column chromatography silica gel) are added in, after mixing, solvent is evaporated off, obtains dry concentrate and silicon
Mixture is filled column, then using volume ratio as 5 by the mixture of glue:1 petrol ether/ethyl acetate mixed solution is eluant, eluent, is washed
De-, (solvent is ethyl acetate/petroleum ether=1 to TLC tracing detections:3 (v/v)), it is collected according to TLC detections containing shown in formula (IV)
Compound eluent (Rf values be 0.5), collection liquid concentration, 50 DEG C of faint yellow solids productions being dried to obtain shown in formula (IV)
Object, yield 80.2%, 164~166 DEG C of fusing point.1H NMR and IR is the same as embodiment 1.
Embodiment 5:Nitro benzo [d] azepineThe preparation of base quinazoline (IV)
Successively by the chloro- 6- nitro-quinazolines (III) of 1.20 grams of (5.73mmol) 4- and 1.79 grams of (5.15mmol) compounds
(II), 1.04 grams of (8.58mmol) N, N- dimethylanilines, 12 milliliters of n,N-Dimethylformamide are added in 50 milliliters of reaction bulb,
120 DEG C are heated to, (solvent is ethyl acetate/petroleum ether=1 to TLC tracing detections:3 (v/v)), be stirred to react 0.5 it is small when, close
Reaction is closed, solvent is evaporated off in reaction solution, and 20 milliliters of tetrahydrofurans are added in obtained concentrate and are dissolved, obtain lysate, to
5.0 grams of column chromatography silica gels (300~400 mesh column chromatography silica gel) are added in lysate, after mixing, solvent is evaporated off, are obtained dry dense
Mixture is filled column, then using volume ratio as 1 by the mixture of contracting object and silica gel:1 petrol ether/ethyl acetate mixed solution is
Eluant, eluent, elution, (solvent is ethyl acetate/petroleum ether=1 to TLC tracing detections:3 (v/v)), it is collected and contained according to TLC detections
The eluent (Rf values be 0.5) of formula (IV) compound represented, collection liquid concentration, 50 DEG C be dried to obtain it is yellowish shown in formula (IV)
Color solid product, yield 89.6%, 164~166 DEG C of fusing point.1HNMR and IR is the same as embodiment 1.
Embodiment 6:Nitro benzo [d] azepineThe preparation of base quinazoline (IV)
Successively by the chloro- 6- nitro-quinazolines (III) of 1.20 grams of (5.73mmol) 4- and 2.39 grams of (6.87mmol) compounds
(II), 3.62 grams of (45.76mmol) pyridines, 20 milliliters of propyl alcohol are added in 50 milliliters of reaction bulb, are heated to 40 DEG C, TLC tracking
(solvent is ethyl acetate/petroleum ether=1 for detection:3 (v/v)), be stirred to react 10 it is small when, close reaction, reaction solution is evaporated off molten
Agent adds in 20 milliliters of ethyl acetate in obtained concentrate and is dissolved, obtains lysate, 3.5 grams of columns are added in into lysate
Chromatographic silica gel (300~400 mesh column chromatography silica gel) after mixing, is evaporated off solvent, obtains the mixture of dry concentrate and silica gel,
Mixture is filled into column, then using volume ratio as 1:1 petrol ether/ethyl acetate mixed solution is eluant, eluent, is eluted, TLC tracking
(solvent is ethyl acetate/petroleum ether=1 for detection:3 (v/v)), it is collected according to TLC detections containing formula (IV) compound represented
Eluent (Rf values are 0.5), collection liquid concentration, 50 DEG C are dried to obtain the faint yellow solid product shown in formula (IV), yield
78.3%, 164~166 DEG C of fusing point.1H NMR and IR is the same as embodiment 1.
Embodiment 7:Amino benzo [d] azepineThe preparation of base quinazoline (V)
0.40 gram of (0.77mmol) nitro benzo [d] azepine successively prepared by 1 method of embodimentBase quinazoline (IV),
0.40 gram of (6.34mmol) ammonium formate, 0.04 gram of 5%Pd/C, 4.0 milliliters of chloroforms are added in reaction bulb, 25 DEG C of stirrings of room temperature,
(solvent is ethyl acetate/petroleum ether=1 to TLC tracing detections:1 (v/v)), when reaction 12 is small, filtering, filtrate concentration, 25 DEG C
Vacuum drying obtains faint yellow solid product amino benzo [d] azepineBase quinazoline (V), yield 98.2%, fusing point 122~
126℃。1H NMR(500MHz,CDCl3)δ:3.40-3.48(m,2H),3.71(s,3H),3.82(s,3H),3.83(s,3H),
3.87-3.98 (m, 5H), 4.45 (dd, J=6.3,13.8Hz, 1H), 4.95 (dd, J=6.5,9.2Hz, 1H), 6.47 (s,
1H), 6.90 (d, J=8.7Hz, 2H), 6.95 (d, J=2.5Hz, 1H), 7.11 (d, J=8.6Hz, 2H), 7.15 (dd, J=
8.9,2.5Hz, 1H), 7.69 (d, J=8.9Hz, 1H), 8.50 (s, 1H).IR(KBr,cm-1)ν:3368,3215,2932,
2825,1628,1566,1512,1487,1353,1248,1036,834。
Embodiment 8:Amino benzo [d] azepineThe preparation of base quinazoline (V)
0.40 gram of (0.77mmol) nitro benzo [d] azepine successively prepared by 2 method of embodimentBase quinazoline (IV),
1.20 grams of (19.18mmol) 80wt% hydrazine hydrates, 0.20 gram of 5%Pd/C, 20.0 milliliters of toluene are added to 50 milliliters of reaction bulb
In, 100 DEG C are heated to, (solvent is ethyl acetate/petroleum ether=1 to TLC tracing detections:1 (v/v)), it is small to be stirred to react 0.5
When, cold filtration, filtrate concentrates, and 25 DEG C of vacuum drying obtain faint yellow solid product amino benzo [d] azepineBase quinazoline
(V), yield 100.0%, 122~126 DEG C of fusing point.1H NMR and IR is the same as embodiment 7.
Embodiment 9:Amino benzo [d] azepineThe preparation of base quinazoline (V)
0.40 gram of (0.77mmol) nitro benzo [d] azepine successively prepared by 3 method of embodimentBase quinazoline (IV),
0.08 gram of concentrated hydrochloric acid (mass concentration 36~38%), 0.40 gram of iron powder, 20.0 ml methanols are added in 50 milliliters of reaction bulb,
40 DEG C are heated to, (solvent is ethyl acetate/petroleum ether=1 to TLC tracing detections:1 (v/v)), be stirred to react 8 it is small when, cooling
Filtering, filtrate concentration, 25 DEG C of vacuum drying obtain faint yellow solid product amino benzo [d] azepineBase quinazoline (V) is received
Rate 94.1%, 122~126 DEG C of fusing point.1HNMR and IR is the same as embodiment 7.
Embodiment 10:Amino benzo [d] azepineThe preparation of base quinazoline (V)
0.40 gram of (0.77mmol) nitro benzo [d] azepine successively prepared by 4 method of embodimentBase quinazoline (IV),
0.40 gram of acetic acid, 1.20 grams of iron powders, 20.0 milliliters of isopropanols are added in 50 milliliters of reaction bulb, are heated to 80 DEG C, TLC tracking
(solvent is ethyl acetate/petroleum ether=1 for detection:1 (v/v)), be stirred to react 3 it is small when, cold filtration, filtrate concentration, 25 DEG C
Vacuum drying obtains faint yellow solid product amino benzo [d] azepineBase quinazoline (V), yield 97.5%, fusing point 122~
126℃。1H NMR and IR is the same as embodiment 7.
Embodiment 11:Pivaloyl amino benzo [d] azepineThe preparation of base quinazoline (I)
0.27 gram of (0.55mmol) amino benzo [d] azepine successively prepared by 7 method of embodimentBase quinazoline (V),
0.13 gram of (1.64mmol) pyridine, 3 milliliters of tetrahydrofurans are added in reaction bulb, and 0.531 gram is added dropwise under -10 DEG C of stirring conditions
(4.40mmol) pivaloyl chloride, drop finish, and (solvent is ethyl acetate/petroleum ether=1 to TLC tracing detections:1), under the conditions of -10 DEG C
React 12 it is small when, filtering, filtrate steaming removal solvent, concentrate add in 10 milliliters of ethyl acetate dissolved, obtain lysate, Xiang Rong
It solves and 0.60 gram of column chromatography silica gel (300~400 mesh column chromatography silica gel) is added in liquid, after mixing, solvent is evaporated off, obtains dry concentration
Mixture is filled column, then using volume ratio as 1 by the mixture of object and silica gel:10 petrol ether/ethyl acetate mixed solution is to wash
De- agent, elution, (solvent is ethyl acetate/petroleum ether=1 to TLC tracing detections:1 (v/v)), it is collected according to TLC detections containing formula
(I) eluent (Rf values are 0.5) of compound represented, collection liquid concentration, 50 DEG C are dried to obtain the pivaloyl ammonia shown in formula (I)
Base benzo [d] azepineBase quinazoline pale solid, yield 64.2%, 131~133 DEG C of fusing point.1H NMR(500MHz,
[D6]DMSO)δ:1.29(s,9H),3.22-3.28(m,1H),3.38-3.42(m,1H),3.68(s,3H),3.69(s,3H),
3.73 (s, 3H), 3.78-3.84 (m, 1H), 3.87-3.96 (m, 2H), 4.49 (dd, J=8.2,14.7,1H), 5.26 (t, J=
8.6Hz, 1H), 6.85 (s, 1H), 6.89 (d, J=8.8Hz, 2H), 7.08 (d, J=8.7Hz, 2H), 7.69 (d, J=9.0,
1H), 7.88 (dd, J=2.2,9.2Hz, 1H), 8.44 (s, 1H), 8.66 (s, 1H), 9.55 (s, 1H).HRMS-ESI m/z:
575.2417[M+H]+。IR(KBr,cm-1)ν:2966,2921,2868,1665,1557,1522,1510,1490,1163,
1349,1248,1036,847。
Embodiment 12:Pivaloyl amino benzo [d] azepineThe preparation of base quinazoline (I)
0.27 gram of (0.55mmol) amino benzo [d] azepine successively prepared by 8 method of embodimentBase quinazoline (V),
0.04 gram of (0.55mmol) diethylamine, 10.0 milliliters of chloroforms are added in 50 milliliters of reaction bulb, are added dropwise under 10 DEG C of stirring conditions
0.066 gram of (0.55mmol) pivaloyl chloride and 5.0 milliliters of chloroform mixed solutions, drop finish, and (solvent is acetic acid to TLC tracing detections
Ethyl ester/petroleum ether=1:1 (v/v)), when reaction 8 is small under the conditions of 10 DEG C, filtering, filtrate steaming removal solvent, concentrate adds in 20 milliliters
Ethyl alcohol is dissolved, and obtains lysate, and 0.26 gram of column chromatography silica gel (300~400 mesh column chromatography silica gel) is added in into lysate,
After mixing, solvent is evaporated off, obtains the mixture of dry concentrate and silica gel, mixture is filled into column, then using volume ratio as 1:5
Petrol ether/ethyl acetate mixed solution is eluant, eluent, and elution, (solvent is ethyl acetate/petroleum ether=1 to TLC tracing detections:1
(v/v)) eluent (Rf values are 0.5) containing formula (I) compound represented, is collected according to TLC detections, collection liquid concentrates, 50 DEG C
It is dried to obtain pivaloyl amino benzo [d] azepine shown in formula (I)Base quinazoline pale solid, yield 74.7%, fusing point
131~133 DEG C.1H NMR and IR is same
Embodiment 11.
Embodiment 13:Pivaloyl amino benzo [d] azepineThe preparation of base quinazoline (I)
0.27 gram of (0.55mmol) amino benzo [d] azepine successively prepared by 9 method of embodimentBase quinazoline (V),
0.111 gram of (1.10mmol) triethylamine, 10.0 milliliters of ethyl acetate are added in 50 milliliters of reaction bulb, under 0 DEG C of stirring condition
0.133 gram of (1.10mmol) pivaloyl chloride and 5.0 milliliters of ethyl acetate solutions are added dropwise, drop finishes, and (solvent is TLC tracing detections
Ethyl acetate/petroleum ether=1:1) when, reaction 6 is small under the conditions of 25 DEG C, filtering, filtrate steaming removal solvent, concentrate adds in 20 milliliters
Chloroform is dissolved, and obtains lysate, and 0.30 gram of column chromatography silica gel (300~400 mesh column chromatography silica gel) is added in into lysate,
After mixing, solvent is evaporated off, obtains the mixture of dry concentrate and silica gel, mixture is filled into column, then using volume ratio as 10:1
Petrol ether/ethyl acetate mixed solution for eluant, eluent, elution, TLC tracing detections (solvent for ethyl acetate/petroleum ether=
1:1 (v/v)), the eluent (Rf values are 0.5) containing formula (I) compound represented is collected according to TLC detections, collection liquid concentrates, and 50
DEG C it is dried to obtain pivaloyl amino benzo [d] azepine shown in formula (I)Base quinazoline pale solid, yield 50.5% melt
131~133 DEG C of point.1H NMR and IR is the same as embodiment 11.
Embodiment 14:Pivaloyl amino benzo [d] azepineThe preparation of base quinazoline (I)
0.27 gram of (0.55mmol) amino benzo [d] azepine successively prepared by 10 method of embodimentBase quinazoline
(V), 0.067 gram of (0.55mmol) 4-dimethylaminopyridine, 20.0 milliliters of toluene are added in 50 milliliters of reaction bulb, and 5 DEG C are stirred
The solution of 0.410 gram of (2.20mmol) pivalic acid acid anhydride and 7.0 milliliters of toluene is added dropwise under the conditions of mixing, drop finishes, and is heated to 50 DEG C, TLC
(solvent is ethyl acetate/petroleum ether=1 to tracing detection:1) when, reaction 3 is small, filtering, filtrate steaming removal solvent, concentrate addition
20 milliliters of tetrahydrofurans are dissolved, and obtain lysate, and 0.40 gram of column chromatography silica gel (300~400 mesh column is added in into lysate
Chromatographic silica gel), after mixing, solvent is evaporated off, obtains the mixture of dry concentrate and silica gel, mixture is filled into column, then with body
Product is than being 5:1 petrol ether/ethyl acetate mixed solution be eluant, eluent, elution, TLC tracing detections (solvent for ethyl acetate/
Petroleum ether=1:1 (v/v)), the eluent (Rf values are 0.5) containing formula (I) compound represented is collected according to TLC detections, is collected
Liquid concentrates, 50 DEG C of pivaloyl amino benzo [d] azepines being dried to obtain shown in formula (I)Base quinazoline pale solid, yield
57.4% 131~133 DEG C of fusing point.1H NMR and IR is the same as embodiment 11.
Embodiment 15:Pivaloyl amino benzo [d] azepineThe preparation of base quinazoline (I)
0.27 gram of (0.55mmol) amino benzo [d] azepine successively prepared by 7 method of embodimentBase quinazoline (V),
0.213 gram of (1.65mmol) quinoline, 15.0 milliliters of benzene are added in 50 milliliters of reaction bulb, are added dropwise under -10 DEG C of stirring conditions
The solution of 0.265 gram of (2.20mmol) pivaloyl chloride and 5.0 milliliters of benzene, drop finish, TLC tracing detections (solvent for ethyl acetate/
Petroleum ether=1:1) when, reaction 12 is small under the conditions of -10 DEG C, filtering, filtrate steaming removal solvent, concentrate adds in 20 milliliters of tetrahydrofurans
It is dissolved, obtains lysate, 0.40 gram of column chromatography silica gel (300~400 mesh column chromatography silica gel), mixing are added in into lysate
Afterwards, solvent is evaporated off, obtains the mixture of dry concentrate and silica gel, mixture is filled into column, then using volume ratio as 1:1 oil
Ether/ethyl acetate mixture is eluant, eluent, and elution, (solvent is ethyl acetate/petroleum ether=1 to TLC tracing detections:1(v/
V)), the eluent (Rf values are 0.5) containing formula (I) compound represented, collection liquid concentration, 50 DEG C of dryings are collected according to TLC detections
Obtain pivaloyl amino benzo [d] azepine shown in formula (I)Base quinazoline pale solid, yield 70.9%, fusing point 131~
133℃。1H NMR and IR is the same as embodiment 11.
Embodiment 16:Pivaloyl amino benzo [d] azepineThe preparation of base quinazoline (I)
0.27 gram of (0.55mmol) amino benzo [d] azepine successively prepared by 7 method of embodimentBase quinazoline (V),
0.164 gram of (1.10mmol) 4- pyrollidinopyridine, 15.0 milliliters of dichloromethane are added in 50 milliliters of reaction bulb, and 10 DEG C are stirred
0.133 gram of (1.10mmol) pivaloyl chloride and 5.0 milliliters of dichloromethane solutions are added dropwise under the conditions of mixing, drop finishes, TLC tracing detections
(solvent is ethyl acetate/petroleum ether=1:1) when, reaction 8 is small under the conditions of 10 DEG C, filtering, filtrate steaming removal solvent, concentrate adds
Enter 20 milliliters of ethyl alcohol to be dissolved, obtain lysate, 0.50 gram of column chromatography silica gel (300~400 mesh column layer is added in into lysate
Analyse silica gel), after mixing, solvent is evaporated off, obtains the mixture of dry concentrate and silica gel, mixture is filled into column, then with volume
Than for 10:1 petrol ether/ethyl acetate mixed solution be eluant, eluent, elution, TLC tracing detections (solvent for ethyl acetate/
Petroleum ether=1:1 (v/v)), the eluent (Rf values are 0.5) containing formula (I) compound represented is collected according to TLC detections, is collected
Liquid concentrates, 50 DEG C of pivaloyl amino benzo [d] azepines being dried to obtain shown in formula (I)Base quinazoline pale solid, yield
68.6%, 131~133 DEG C of fusing point.1H NMR and IR is the same as embodiment 11.
Embodiment 17:Active anticancer testing in vitro
(1) compound obtained (I), (IV) and (V) MCF-7 cell strainHJ2mm biological activity test has been subjected to.
Test method:Tetrazolium reduction method (mtt assay).
Cell line:MCF-7 cell strainHJ2mm.Above-mentioned tumor cell line is purchased from Chinese Academy of Sciences's Shanghai school of life and health sciences
Cell bank.
Experimental procedure is as follows:
(a) preparation of sample:For solvable sample, dissolved per 1mg with 40 μ L DMSO, take 2 μ L dilute with 1000 μ L culture mediums
It releases, makes concentration for 100 μ g/mL, then with culture solution serial dilution to concentration.
(b) culture of cell
1. the preparation of culture medium:Containing 800,000 units of Penicillin, 1.0g strepto-s in per 1000mL DMEM culture mediums (Gibco)
Element, 10% inactivated fetal bovine serum.
2. the culture of cell:By tumor cell inoculation in culture medium, 37 DEG C are put, 5%CO2It is cultivated in incubator, 3~5d
Passage.
3. determination sample is to the inhibitory action of growth of tumour cell
10th generation cell EDTA- pancreatin digestive juice is digested, and 1 × 10 is diluted to culture medium6/ mL is added to 96 holes
In Tissue Culture Plate, per 100 μ L of hole, 37 DEG C are put, 5%CO2It is cultivated in incubator.After inoculation for 24 hours, it is separately added into dilute with culture medium
100 μ g/mL, the 10 μ g/mL and 1 μ g/mL samples released, per 100 μ L of hole, each concentration adds 3 holes, puts 37 DEG C, 5%CO2Incubator
Middle culture adds in the MTT of 5mg/mL after 72h in cell culture well, per 10 μ L of hole, puts 37 DEG C of incubation 3h, DMSO is added in, per hole
150 μ L, are vibrated with oscillator, and Shi Jia Za is completely dissolved, with microplate reader under 570nm wavelength colorimetric.To be free of under similarity condition
Sample, the cell of medium culture containing similary concentration DMSO calculate IC of the sample to growth of tumour cell as control50。
The results are shown in Table 1 for test:
The inhibitory action that 1. compound of table (I), (IV) and (V) grows cancer cell line MCF-7
(2) according to embodiment 11, pivaloyl chloride is used into 4- iodobenzoyl chlorides, 3- methoxy benzoyl chlorides or cinnamoyl respectively
Chloro replaces, other operations have been respectively synthesized quinazoline compounds (a), (b) and (c), structure are as follows with embodiment 11:
According to the above method by quinazoline compounds (a) obtained, (b) and (c) has carried out Breast cancer lines
MCF-7 biological activity tests, test result show quinazoline compounds (a), and (b) and (c) is to MCF-7 cell strainHJ2mm
The equal unobvious of inhibition, compound (a), (b) and (c) can not show a candle to chemical combination to the active anticancer of MCF-7 cell strainHJ2mm
Object (I).Concrete outcome is as shown in table 2:
The inhibitory action that 2. compound (a) of table, (b) and (c) grow cancer cell line MCF-7
Above-mentioned active anticancer testing in vitro experiment shows:The similar compound (a) of other 3 structures, (b) and (c) is to people
The equal unobvious of inhibitory action of breast cancer cell line mcf-7 growth.Compound (I) grows MCF-7 cell strainHJ2mm
Inhibitory action is notable, hence it is evident that better than compound (a), (b) and (c).
(3) method of reference literature (Rao, G.-W.et al.ChemMedChem, 2013,8 (6), 928-933) is prepared into
To 4- chloro-quinazolines, further according to embodiment 1, the chloro- 6- nitro-quinazolines of 4- are replaced with 4- chloro-quinazolines, other operations are the same as implementation
Example 1, has synthesized quinazoline compounds (d), and structure is as follows:
Quinazoline compounds (d) obtained have been carried out MCF-7 cell strainHJ2mm biology according to the above method to live
Property test, test result shows that quinazoline compounds (d) can not show a candle to chemical combination to the active anticancer of MCF-7 cell strainHJ2mm
Object (I).Concrete outcome is as shown in table 3:
The inhibitory action that 3. compound (d) of table grows cancer cell line MCF-7
(4) according to embodiment 11, pivaloyl chloride is used into chlorobenzoyl chloride, butyl chloride, propionyl chloride, chloracetyl chloride or isobutyl respectively
Acyl chlorides replaces, other operations have been respectively synthesized quinazoline compounds (e), (f), (g), (h) and (j), structure with embodiment 11
It is as follows:
Quinazoline compounds (e) obtained, (f), (g), (h) and (j) have been carried out by human breast carcinoma according to the above method
Cell line MCF-7 biological activity tests, test result show quinazoline compounds (e), (f), (g), (h) with (j) to human milk
The active anticancer of adenocarcinoma cell strain MCF-7 is not so good as compound (I).Concrete outcome is as shown in table 4:
The inhibitory action that 4. compound (e) of table, (f), (g), (h) and (j) grow cancer cell line MCF-7
Embodiment 18:Active anticancer testing in vitro
(1) compound obtained (I) and (IV) human lung cancer cell lines A-549 biological activity test has been subjected to.
Test method:Tetrazolium reduction method (mtt assay).
Cell line:Human lung cancer cell lines A-549.Above-mentioned tumor cell line is thin purchased from Chinese Academy of Sciences's Shanghai school of life and health sciences
Born of the same parents storehouse.
Experimental procedure is as follows:
(a) preparation of sample:For solvable sample, dissolved per 1mg with 40 μ L DMSO, take 2 μ L dilute with 1000 μ L culture mediums
It releases, makes concentration for 100 μ g/mL, then with culture solution serial dilution to concentration.
(b) culture of cell
1. the preparation of culture medium:Containing 800,000 units of Penicillin, 1.0g strepto-s in per 1000mL DMEM culture mediums (Gibco)
Element, 10% inactivated fetal bovine serum.
2. the culture of cell:By tumor cell inoculation in culture medium, 37 DEG C are put, 5%CO2It is cultivated in incubator, 3~5d
Passage.
3. determination sample is to the inhibitory action of growth of tumour cell
2nd generation cell EDTA- pancreatin digestive juice is digested, and 1 × 10 is diluted to culture medium6It is thin to be added to 96 holes by/mL
In born of the same parents' culture plate, per 100 μ L of hole, 37 DEG C are put, 5%CO2It is cultivated in incubator.After inoculation for 24 hours, it is separately added into and is diluted with culture medium
100 μ g/mL, 10 μ g/mL and 1 μ g/mL samples, per 100 μ L of hole, each concentration adds 3 holes, puts 37 DEG C, 5%CO2In incubator
It cultivates, adds in the MTT of 5mg/mL after 72h in cell culture well, per 10 μ L of hole, put 37 DEG C of incubation 3h, add in DMSO, every hole
150 μ L, are vibrated with oscillator, and Shi Jia Za is completely dissolved, with microplate reader under 570nm wavelength colorimetric.To be free of under similarity condition
Sample, the cell of the medium culture containing similary concentration DMSO calculate IC of the sample to growth of tumour cell as control50。
The results are shown in Table 5 for test:
The inhibitory action that 5. compound of table (I) and (IV) grow cancer cell line A-549
(2) according to embodiment 11, pivaloyl chloride is used into 4- iodobenzoyl chlorides, 3- methoxy benzoyl chlorides or cinnamoyl respectively
Chloro replaces, other operations have been respectively synthesized quinazoline compounds (a), (b) and (c), structure are as follows with embodiment 11:
According to the above method by quinazoline compounds (a) obtained, (b) and (c) has carried out human lung cancer cell lines A-549
Biological activity test, test result show quinazoline compounds (a), and (b) and (c) inhibits to imitate to human lung cancer cell lines A-549
The equal unobvious of fruit, compound (a), (b) and (c) can not show a candle to the active anticancer of human lung cancer cell lines A-549 compound (I).Tool
The results are shown in Table 6 for body:
The inhibitory action that 6. compound (a) of table, (b) and (c) grow cancer cell line A-549
Above-mentioned active anticancer testing in vitro experiment shows:The similar compound (a) of other 3 structures, (b) and (c) is to people
The equal unobvious of inhibitory action of lung cancer cell line A-549 growths.The inhibition that compound (I) grows human lung cancer cell lines A-549
Effect is notable, hence it is evident that better than compound (a), (b) and (c).
(3) method of reference literature (Rao, G.-W.et al.ChemMedChem, 2013,8 (6), 928-933) is prepared into
To 4- chloro-quinazolines, further according to embodiment 1, the chloro- 6- nitro-quinazolines of 4- are replaced with 4- chloro-quinazolines, other operations are the same as implementation
Example 1, has synthesized quinazoline compounds (d), and structure is as follows:
Quinazoline compounds (d) obtained have been carried out by human lung cancer cell lines A-549 bioactivity according to the above method
Test, test result show that quinazoline compounds (d) can not show a candle to compound to the active anticancer of human lung cancer cell lines A-549
(Ⅰ).Concrete outcome is as shown in table 7:
The inhibitory action that 7. compound (d) of table grows cancer cell line A-549
(4) according to embodiment 11, pivaloyl chloride is replaced respectively with chlorobenzoyl chloride, chloracetyl chloride or isobutyryl chloride, other
Operation has been respectively synthesized quinazoline compounds (e), (h) and (j), structure is as follows with embodiment 11:
Quinazoline compounds (e) obtained, (h) and (j) have been carried out by human lung cancer cell lines A-549 according to the above method
Biological activity test, test result show the anticancer of quinazoline compounds (e), (h) with (j) to human lung cancer cell lines A-549
Activity is not so good as compound (I).Concrete outcome is as shown in table 8:
The inhibitory action that 8. compound (e) of table, (h) and (j) grow cancer cell line A-549
Embodiment 19:Active anticancer testing in vitro
(1) compound obtained (I) people in loop strain HL-60 biological activity tests have been subjected to.
Test method:Tetrazolium reduction method (mtt assay).
Cell line:People in loop strain HL-60.Above-mentioned tumor cell line is purchased from Chinese Academy of Sciences's Shanghai life
Academy of sciences's cell bank.
Experimental procedure is as follows:
(a) preparation of sample:For solvable sample, dissolved per 1mg with 40 μ L DMSO, take 2 μ L dilute with 1000 μ L culture mediums
It releases, makes concentration for 100 μ g/mL, then with culture solution serial dilution to concentration.
(b) culture of cell
1. the preparation of culture medium:Containing 800,000 units of Penicillin, 1.0g strepto-s in per 1000mL DMEM culture mediums (Gibco)
Element, 10% inactivated fetal bovine serum.
2. the culture of cell:By tumor cell inoculation in culture medium, 37 DEG C are put, 5%CO2It is cultivated in incubator, 3~5d
Passage.
3. determination sample is to the inhibitory action of growth of tumour cell
2nd generation cell EDTA- pancreatin digestive juice is digested, and 1 × 10 is diluted to culture medium6It is thin to be added to 96 holes by/mL
In born of the same parents' culture plate, per 100 μ L of hole, 37 DEG C are put, 5%CO2It is cultivated in incubator.After inoculation for 24 hours, it is separately added into and is diluted with culture medium
100 μ g/mL, 10 μ g/mL and 1 μ g/mL samples, per 100 μ L of hole, each concentration adds 3 holes, puts 37 DEG C, 5%CO2In incubator
It cultivates, adds in the MTT of 5mg/mL after 72h in cell culture well, per 10 μ L of hole, put 37 DEG C of incubation 3h, add in DMSO, every hole
150 μ L, are vibrated with oscillator, and Shi Jia Za is completely dissolved, with microplate reader under 570nm wavelength colorimetric.To be free of under similarity condition
Sample, the cell of the medium culture containing similary concentration DMSO calculate IC of the sample to growth of tumour cell as control50。
The results are shown in Table 9 for test:
The inhibitory action that 9. compound of table (I) grows cancer cell line HL-60
(2) according to embodiment 11, pivaloyl chloride is replaced respectively with 3- methoxy benzoyl chlorides or cinnamoyl chloride, other behaviour
Make with embodiment 11, be respectively synthesized quinazoline compounds (b) and (c), structure is as follows:
Quinazoline compounds (b) obtained and (c) have been carried out by people in loop strain according to the above method
HL-60 biological activity tests, test result show quinazoline compounds (b) and (c) to people in loop strain HL-
The equal unobvious of 60 inhibitions, compound (b) and (c) can not show a candle to the active anticancer of people in loop strain HL-60
Compound (I).Concrete outcome is as shown in table 10:
The inhibitory action that 10. compound (b) of table and (c) grow cancer cell line HL-60
Above-mentioned active anticancer testing in vitro experiment shows:The similar compound (b) of other 2 structures and (c) are to the early children of people
The equal unobvious of inhibitory action of grain leukemia cell line HL-60 growth.Compound (I) is to people in loop strain HL-
The inhibitory action of 60 growths is notable, hence it is evident that better than compound (b) and (c).
(3) according to embodiment 11, pivaloyl chloride is replaced respectively with cyclohexyl methyl chloro-formate or propionyl chloride, other behaviour
Make with embodiment 11, be respectively synthesized quinazoline compounds (k) and (g), structure is as follows:
Quinazoline compounds (k) obtained and (g) have been carried out by people in loop strain according to the above method
HL-60 biological activity tests, test result show quinazoline compounds (k) and (g) to people in loop strain HL-
60 active anticancer is not so good as compound (I).Concrete outcome is as shown in table 11:
The inhibitory action that 11. compound (k) of table and (g) grow cancer cell line HL-60
Embodiment 20:Active anticancer testing in vitro
(1) compound obtained (I) human cervical carcinoma cell lines Siha biological activity tests have been subjected to.
Test method:Tetrazolium reduction method (mtt assay).
Cell line:Human cervical carcinoma cell lines Siha.Above-mentioned tumor cell line is purchased from Chinese Academy of Sciences's Shanghai school of life and health sciences
Cell bank.
Experimental procedure is as follows:
(a) preparation of sample:For solvable sample, dissolved per 1mg with 40 μ L DMSO, take 2 μ L dilute with 1000 μ L culture mediums
It releases, makes concentration for 100 μ g/mL, then with culture solution serial dilution to concentration.
(b) culture of cell
1. the preparation of culture medium:Containing 800,000 units of Penicillin, 1.0g strepto-s in per 1000mL DMEM culture mediums (Gibco)
Element, 10% inactivated fetal bovine serum.
2. the culture of cell:By tumor cell inoculation in culture medium, 37 DEG C are put, 5%CO2It is cultivated in incubator, 3~5d
Passage.
3. determination sample is to the inhibitory action of growth of tumour cell
2nd generation cell EDTA- pancreatin digestive juice is digested, and 1 × 10 is diluted to culture medium6It is thin to be added to 96 holes by/mL
In born of the same parents' culture plate, per 100 μ L of hole, 37 DEG C are put, 5%CO2It is cultivated in incubator.After inoculation for 24 hours, it is separately added into and is diluted with culture medium
100 μ g/mL, 10 μ g/mL and 1 μ g/mL samples, per 100 μ L of hole, each concentration adds 3 holes, puts 37 DEG C, 5%CO2In incubator
It cultivates, adds in the MTT of 5mg/mL after 72h in cell culture well, per 10 μ L of hole, put 37 DEG C of incubation 3h, add in DMSO, every hole
150 μ L, are vibrated with oscillator, and Shi Jia Za is completely dissolved, with microplate reader under 570nm wavelength colorimetric.To be free of under similarity condition
Sample, the cell of the medium culture containing similary concentration DMSO calculate IC of the sample to growth of tumour cell as control50.It surveys
The result of examination is as shown in table 12:
The inhibitory action that 12. compound of table (I) grows cancer cell line Siha
(2) according to embodiment 11, pivaloyl chloride is replaced respectively with 3- methoxy benzoyl chlorides or cinnamoyl chloride, other behaviour
Make with embodiment 11, be respectively synthesized quinazoline compounds (b) and (c), structure is as follows:
Quinazoline compounds (b) obtained and (c) have been carried out by human cervical carcinoma cell lines Siha lifes according to the above method
Object active testing, test result show quinazoline compounds (b) and (c) to human cervical carcinoma cell lines Siha inhibitions not
Substantially, compound (b) and (c) can not show a candle to the active anticancer of human cervical carcinoma cell lines Siha compound (I).Concrete outcome such as table
Shown in 13:
The inhibitory action that 13. compound (b) of table and (c) grow cancer cell line Siha
Above-mentioned active anticancer testing in vitro experiment shows:The similar compound (b) of other 2 structures and (c) are to people's uterine neck
The equal unobvious of inhibitory action of cancer cell line Siha growths.Compound (I) makees the inhibition that human cervical carcinoma cell lines Siha is grown
With notable, hence it is evident that better than compound (b) and (c).
(3) according to embodiment 11, pivaloyl chloride is replaced respectively with butyl chloride or cyclohexyl methyl chloro-formate, other behaviour
Make with embodiment 11, be respectively synthesized quinazoline compounds (f) and (k), structure is as follows:
Quinazoline compounds (f) obtained and (k) have been carried out by human cervical carcinoma cell lines Siha lifes according to the above method
Object active testing, test result show that compound (f) and (k) can not show a candle to chemical combination to the active anticancer of human cervical carcinoma cell lines Siha
Object (I).Concrete outcome is as shown in table 14:
The inhibitory action that 14. compound (f) of table and (k) grow cancer cell line Siha
Claims (10)
1. a kind of pivaloyl amino benzo [d] azepine shown in formula (I)Base quinazoline compounds:
2. a kind of pivaloyl amino benzo [d] azepine shown in formula as described in claim 1 (I)Base quinazoline compounds
Preparation method, it is characterised in that the method is:
(1) compound shown in formula (II) is mixed with compound shown in formula (III), in organic solvent A, in basic catalyst B's
Under effect, 25~120 DEG C are reacted, and after the reaction was complete, reaction solution is isolated and purified, and compound shown in formula (IV) is made;Institute
Organic solvent A is stated selected from one of following:Chloroform, toluene, methanol, ethyl alcohol, propyl alcohol, isopropanol, acetonitrile or N, N- dimethyl formyl
Amine;The basic catalyst B is selected from one of following:Pyridine, diethylamine, triethylamine, quinoline, N, N- dimethylanilines, 4- diformazans
Aminopyridine, 4- pyrollidinopyridines or sodium carbonate;
(2) formula (IV) compound represented obtained by step (1) is dissolved in organic solvent D, under reducing agent E effects, 25
~100 DEG C the reaction was complete, reacting liquid filtering, and formula (V) compound represented is made in the concentrate drying after filtrate decompression concentration;
The organic solvent D is one of following:Chloroform, toluene, methanol, ethyl alcohol, propyl alcohol, isopropanol, acetonitrile or N, N- dimethyl formyl
Amine;The reducing agent E is one of following:Iron powder/concentrated hydrochloric acid, iron powder/acetic acid, palladium carbon/ammonium formate or palladium carbon/hydrazine hydrate;It is described
Iron powder/concentrated hydrochloric acid refers to that the mixing of iron powder and concentrated hydrochloric acid arbitrary proportion, iron powder/acetic acid refer to the mixed of iron powder and acetic acid arbitrary proportion
It closes, the palladium carbon/ammonium formate refers to the mixing of palladium carbon and ammonium formate arbitrary proportion, and the palladium carbon/hydrazine hydrate is palladium carbon and hydration
The mixture of hydrazine arbitrary proportion;
(3) compound shown in formula (V) is mixed with pivaloyl chloride or pivalic acid acid anhydride, under basic catalyst F effects, in organic
In solvent G, -10~50 DEG C the reaction was complete, and reaction solution is post-treated, and formula (I) compound represented is made;The base catalysis
Agent F is one of following:Pyridine, diethylamine, triethylamine, quinoline, N, N- dimethylanilines, 4-dimethylaminopyridine, 4- pyrrolidinyls
Pyridine or sodium carbonate;The organic solvent G is one of following:Tetrahydrofuran, dichloromethane, chloroform, ethyl acetate, ether, second
Nitrile, toluene or benzene;
3. method as claimed in claim 2, it is characterised in that:Compound shown in formula (III) described in step (1) and formula (II)
The ratio between shown compound, amount for the substance that feeds intake of basic catalyst B are 1.0 ﹕, 0.8~1.2 ﹕ 1.0~8.0;The organic solvent A
Dosage 10~50mL/g is calculated as with the quality of compound shown in formula (III).
4. method as claimed in claim 2, it is characterised in that:Reaction solution described in step (1) isolates and purifies in step (1)
Method is:After the reaction was complete, solvent is evaporated off in reaction solution, concentrate is taken to be dissolved with organic solvent C, obtains lysate, so
It adds in the column chromatography silica gel of 1.0~2.0 times of weight of concentrate in backward lysate, after mixing, solvent is evaporated off, it is dry, it obtains dense
Mixture is filled column, then using volume ratio as 1 by the mixture of contracting object and silica gel:0.1~10 petroleum ether is mixed with ethyl acetate
Solution is eluant, eluent, collects the efflux containing target components, is concentrated under reduced pressure, dry, obtains formula (IV) compound represented;It is described
Organic solvent C is one of following:Ethyl alcohol, chloroform, tetrahydrofuran or ethyl acetate.
5. method as claimed in claim 2, it is characterised in that:In step (2), when the reducing agent E is iron powder/concentrated hydrochloric acid
Or iron powder/acetic acid, formula (IV) compound represented are with iron powder, the mass ratio that feeds intake of concentrated hydrochloric acid or acetic acid in reducing agent E
1.0 ﹕, 1.0~3.0 ﹕ 0.2~1.0;When the reducing agent E be palladium carbon/ammonium formate or palladium carbon/hydrazine hydrate, shown in formula (IV)
The mass ratio that feeds intake of palladium carbon, ammonium formate or hydrazine hydrate in compound and reducing agent E is 1.0 ﹕, 0.1~0.5 ﹕ 1.0~3.0.
6. method as claimed in claim 2, it is characterised in that:Step (3) carries out as follows:In -10~10 DEG C of items
Under part, into the organic solvent G solution of compound shown in formula (V) and basic catalyst F or toward compound shown in formula (V) and
The organic solvent G solution of pivaloyl chloride or pivalic acid acid anhydride is added dropwise in basic catalyst F, drop finishes, and -10~50 DEG C of reactions 3~12 are small
When, gained reaction solution is post-treated to obtain compound shown in formula (I);Total dosage of the organic solvent G is with formula (V) shownization
The quality for closing object is calculated as 11~100mL/g.
7. method as claimed in claim 2, it is characterised in that:Compound shown in formula (V) described in step (3) and spy penta
Acyl chlorides or pivalic acid acid anhydride, the ratio between the amount for the substance that feeds intake of basic catalyst F are 1 ﹕, 1.0~8.0 ﹕ 1.0~3.0;It is described organic molten
The dosage of agent G is calculated as 11~100mL/g with the quality of compound shown in formula (V).
8. method as claimed in claim 2, it is characterised in that:The method of step (3) reaction solution post processing is:It will reaction
Liquid filters, and filtrate steaming removal solvent takes concentrate to be dissolved with organic solvent H, obtains lysate, is then added in into lysate
After mixing, solvent is evaporated off in the column chromatography silica gel of 1.0~2.0 times of weight of concentrate, dry, obtains the mixing of concentrate and silica gel
Mixture is filled column, then using volume ratio as 1 by object:0.1~10 petroleum ether is eluant, eluent with ethyl acetate mixture, is received
Collect the efflux containing target components, be concentrated under reduced pressure, it is dry, obtain formula (I) compound represented;The organic solvent H is following
One of:Ethyl alcohol, chloroform, tetrahydrofuran or ethyl acetate.
9. pivaloyl amino benzo [d] azepine shown in formula (I) as described in claim 1Base quinazoline compounds are being made
It is standby to prevent or treat the application in human breast carcinoma drug.
10. application as claimed in claim 9, it is characterised in that the drug is with inhibition MCF-7 cell strainHJ2mm
The drug of activity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810070298.1A CN108047206B (en) | 2018-01-24 | 2018-01-24 | Pivaloyl amino benzo [d] azepine * base quinazoline compounds and preparation and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810070298.1A CN108047206B (en) | 2018-01-24 | 2018-01-24 | Pivaloyl amino benzo [d] azepine * base quinazoline compounds and preparation and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108047206A true CN108047206A (en) | 2018-05-18 |
CN108047206B CN108047206B (en) | 2019-11-29 |
Family
ID=62124665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810070298.1A Active CN108047206B (en) | 2018-01-24 | 2018-01-24 | Pivaloyl amino benzo [d] azepine * base quinazoline compounds and preparation and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108047206B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1061411A (en) * | 1990-11-06 | 1992-05-27 | 美国辉瑞有限公司 | Be used to strengthen the active quinazoline derivant of antineoplastic agent |
CN1141633A (en) * | 1994-02-23 | 1997-01-29 | 辉瑞大药厂 | 4-heterocyclyl-substituted Quinazoline derivatives, method for prepn. of same and the use as anti-cancer agent |
WO2006074147A2 (en) * | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
CN103275018A (en) * | 2013-04-26 | 2013-09-04 | 浙江工业大学 | 4-(3-chloro-4-substituted anilino)-6-substituted carbamonyl quinazoline compounds, and preparation method and applications thereof |
-
2018
- 2018-01-24 CN CN201810070298.1A patent/CN108047206B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1061411A (en) * | 1990-11-06 | 1992-05-27 | 美国辉瑞有限公司 | Be used to strengthen the active quinazoline derivant of antineoplastic agent |
CN1141633A (en) * | 1994-02-23 | 1997-01-29 | 辉瑞大药厂 | 4-heterocyclyl-substituted Quinazoline derivatives, method for prepn. of same and the use as anti-cancer agent |
WO2006074147A2 (en) * | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
CN103275018A (en) * | 2013-04-26 | 2013-09-04 | 浙江工业大学 | 4-(3-chloro-4-substituted anilino)-6-substituted carbamonyl quinazoline compounds, and preparation method and applications thereof |
Also Published As
Publication number | Publication date |
---|---|
CN108047206B (en) | 2019-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108084162B (en) | Dimethoxy benzene aminoacetylamino benzo [d] azepine * base quinazoline compounds and preparation and application | |
CN109251196A (en) | Amino benzo [d] azepine * base quinazoline compounds and its preparation method and application | |
CN108042546A (en) | Morpholinyl acetylamino benzo [d] azepine * bases quinazoline compounds are preparing the application in treating uterine neck cancer drug | |
CN108078994A (en) | 6- (2- morpholinyls acetylamino) quinazoline compounds are preparing the application in treating lung-cancer medicament | |
CN108017621A (en) | Morpholinyl acetylamino dimethoxy benzo [d] azepine * bases quinazoline compounds and preparation and application | |
CN108125961A (en) | Morpholinyl acetylamino anisyl benzo-aza * bases quinazoline compounds are preparing the application in treating leukemia medicament | |
CN108014113A (en) | Application of butyrylamidodimethoxybenzo [ d ] aza-based quinazoline compound in preparation of drugs for treating cervical cancer | |
CN108117542A (en) | Propionamido anisyl benzo [d] azepine * bases quinazoline compounds and preparation and application | |
CN108129461A (en) | Benzamido benzo [d] azepine * bases quinazoline compounds and preparation and application | |
CN103254141B (en) | 4-[4-(2-dipropyl aminoacetylamino) anilino]-6-substituted quinazoline compounds and Synthesis and applications | |
CN108047206B (en) | Pivaloyl amino benzo [d] azepine * base quinazoline compounds and preparation and application | |
CN108324717A (en) | Pivaloyl amino chloro benzo [d] azepine * bases quinazoline compounds are preparing the application in treating uterine neck cancer drug | |
CN108329299A (en) | Butyrylamino chloro benzo [ d ] aza-based quinazoline compound, preparation and application thereof | |
CN108295076A (en) | Propionamido dimethoxy benzo [d] azepine * bases quinazoline ditosylate salt is preparing the application in treating lung-cancer medicament | |
CN108276384A (en) | Acetylamino benzo [d] azepine * bases quinazoline compounds and its preparation and application | |
CN105949139B (en) | A kind of sec-butyl diphenyl tetrazine benzamide compound and preparation and application | |
CN108014112A (en) | Adjacent toluidino acetylamino benzo [d] azepine * bases quinazoline compounds are preparing the application in treating lung-cancer medicament | |
CN108309984A (en) | Propionamido quinazoline compounds are preparing the application in treating uterine neck cancer drug | |
CN108324718A (en) | Application of the cyclohexyl methoxy formamido group chloro benzo azepine * bases quinazoline compounds in treating leukemia medicament | |
CN108324719A (en) | Adjacent toluidino acetylamino anisyl benzo-aza * bases quinazoline compounds are preparing the application in treating uterine neck cancer drug | |
CN108329300A (en) | Nitro benzo [d] azepine * base quinazoline compounds and its preparation method and application | |
CN108125962A (en) | Benzo [d] azepine * bases quinazoline compounds are preparing the application in treating lung-cancer medicament | |
CN108033949B (en) | 6- (2- dipropyl aminoacetylamino) quinazoline compounds and preparation and application | |
CN108164510A (en) | Chloro acetylamino benzo [d] azepine * base quinazoline compounds and its preparation method and application | |
CN108014115A (en) | Pivaloyl amino anisyl benzo [d] azepine * bases quinazoline compounds are preparing the application in treating lung-cancer medicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Yuning Inventor after: Rao Guowu Inventor after: Hu Chenghai Inventor before: Rao Guowu Inventor before: Liu Yuning Inventor before: Hu Chenghai |
|
GR01 | Patent grant | ||
GR01 | Patent grant |